At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
Albumin Bound Paclitaxel +1 moredrug
Likely dose
Albumin Bound Paclitaxel 120 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
In Brief
A Phase 2 clinical trial evaluating Albumin Bound Paclitaxel and S-1 for Gastric Cancer. Completed, enrolled 73 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of s-1 plus Albumin Bound Paclitaxel as first-line therapy in the treatment of patients with advanced gastric cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedAug 2014
Primary CompletionFeb 2017
TodayJul 2026
First PostedAug 29, 2014
Enrollment StartFeb 1, 2012
Primary CompletionFeb 1, 2017
TodayJul 1, 2026
Enrollment to primary: 5 yearsPosted 11.8 years ago
Interventions
Albumin Bound Paclitaxeldrug
120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
S-1drug
40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA\>1.5m2,until disease progress or intolerable toxicity.